

PATIENT DEMOGRAPHICS

Patient Name: _____ DOB: _____ Phone: _____
 Address: _____ City/ST/Zip: _____
 Allergies: _____ NKDA Weight: _____ lbs kg Height: _____ in cm
Patient Status: New to Therapy Dose or Frequency Change Order Renewal

INSURANCE INFORMATION: Please attach copy of insurance card (front and back).

DIAGNOSIS*

***ICD 10 Code
Required**

- Myasthenia Gravis without (acute) exacerbation, G70.00
- Myasthenia Gravis with (acute) exacerbation, G70.01
- Other: _____, ICD10 _____

INFUSION ORDERS

MEDICATION	DOSE	DIRECTIONS/DURATION
Rystiggo® (rozanolixizumab)	<input type="checkbox"/> <50kg: 420 mg <input type="checkbox"/> 50kg to <100kg: 560 mg <input type="checkbox"/> ≥100kg: 840 mg	Infuse subcutaneously using a syringe infusion pump at a constant flow rate of 20 mL/hr once weekly x 6 doses <input type="checkbox"/> May repeat above treatment cycle every ____ weeks x 1 year (no sooner than 63 days from the start of the previous treatment cycle) *Observe patient for 15 minutes after completion of infusion.

Is patient currently receiving therapy above from another facility?

Yes No

If yes, Facility Name: _____

Date of last treatment: _____ Date of next treatment: _____

PRE-MEDICATION ORDERS

- No premeds ordered at this time
- Acetaminophen 650mg PO Diphenhydramine 25mg PO
- Methylprednisolone 40mg IVP -OR- Hydrocortisone 100mg IVP
- Other: _____

LAB ORDERS

- Labs to be drawn by:** Infusion Center Referring Physician
- No labs ordered at this time
- CBC q _____ CMP q _____ CRP q _____
- ESR q _____ LFTs q _____ Other: _____

REFERRING PHYSICIAN INFORMATION

Physician Signature: _____ Date: _____
 Physician Name: _____ NPI: _____ TIN: _____ Specialty: _____
 Address: _____ City/ST/Zip: _____
 Contact Person: _____ Phone #: _____ Fax #: _____
 Email Where Follow Up Documentation Should Be Sent: _____

REQUIRED CLINICAL DOCUMENTATION

Please attach medical records: Initial H&P, current MD progress notes, medication list, and labs/test results to support diagnosis.

Clinical Information, select all that apply:

- The patient is positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
Please specify:
 - Anti-acetylcholine receptor (AChR) antibody
 - Anti-muscle-specific tyrosine kinase (MuSK) antibody
- The patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease.
 - Clinical Classification: _____
- The patient has a baseline MG-Activities of Daily Living (MG-ADL) score of ≥ 5.
 - MG-ADL score: _____

LAB AND TEST RESULTS (required)

- Anti-acetylcholine Receptor (AChR) Antibodies
- Anti-muscle-specific tyrosine kinase (MuSK) Antibodies
- Baseline MG-Activities of Daily Living (MG-ADL) Evaluation Form
- Other: _____

PRIOR FAILED THERAPIES

Medication Failed: _____ Dates of Treatment: _____ Reason for D/C: _____
 Medication Failed: _____ Dates of Treatment: _____ Reason for D/C: _____
 Medication Failed: _____ Dates of Treatment: _____ Reason for D/C: _____
 Medication Failed: _____ Dates of Treatment: _____ Reason for D/C: _____
 Medication Failed: _____ Dates of Treatment: _____ Reason for D/C: _____